. 2012 Jun 6;33(6):852–858. doi: 10.1038/aps.2012.44

Table 2. Main PK parameters of total VCR after IV administration of VSLI or VCR. Values are expressed as mean (SD). ^aP<0.05 vs 2.0 mg VCR group. ^bP<0.05 vs 2.0 mg VCR group. ^dP>0.05 vs 1.5 mg·m^-2 single-dose VSLI group. ^eP<0.05 vs 1.5 mg·m^-2 single-dose VSLI group. ^gP>0.05 vs 2.0 mg·m^-2 single-dose VSLI group.

Parameters	Single-dose pharmacokinetic study				Multiple-dose pharmacokinetic study
Parameters	1.5 mg·m⁻² VSLI (n=5)	2.0 mg·m⁻² VSLI (n=6)	2.3 mg·m⁻² VSLI (n=6)	2.0 mg VCR (n=6)	1.5 mg·m⁻² VSLI (n=6)	1.8 mg·m⁻² VSLI (n=6)
C_max/ng·mL⁻¹	141.3 (40.8)^b	127.0 (80.4)^ad	218.7 (127.4)^adg	83.4 (39.5)	134.8 (138.6)^d	85.2 (28.3)^d
AUC_0–t/ng·h·mL⁻¹	205.1 (57.4)^b	201.2 (51.4)^bd	281.8 (95.0)^bdg	121.3 (15.6)	169.8 (88.3)^d	130.3 (15.7)^d
AUC_0–inf/ng·h·mL⁻¹	229.3 (66.3)^b	242.9 (60.8)^bd	316.1 (106.5)^bdg	140.3 (25.0)	216.7 (77.6)^d	155.5 (25.2)^d
MRT_0–t/h	8.9 (1.7)^a	11.8 (1.6)^be	10.6 (2.7)^adg	8.4 (2.8)	5.9 (1.2)^e	5.8 (0.6)^d
MRT_0–inf/h	15.1 (3.9)^a	24.9 (9.4)^ad	17.8 (4.5)^adg	15.9 (8.2)	17.6 (8.2)^d	12.3 (4.7)^d
t_1/2z/h	17.5 (6.7)^a	24.9 (8.3)^ad	19.2 (2.5)^adg	16.0 (7.9)	17.4 (6.2)^d	13.0 (6.0)^d
T_max/h	1.05 (0.04)^a	0.85(0.27)^ad	0.8 (0.27)^adg	0.89 (0.31)	0.93 (0.21)^d	0.83 (0.26)^d
CL_z/L·h⁻¹	7.0 (1.9)^b	8.7 (2.3)^bd	8.0 (2.7)^bdg	14.6 (2.7)	7.6 (2.4)^d	11.8 (1.9)^e
V_z/L	166.3 (42.2)^b	309.0 (119.8)^ae	217.5 (70.8)^adg	321.9 (123.4)	202.1 (112.2)^d	212.7(82.0)^d